Novo Nordisk vows legal action to protect Wegovy pill

medicalxpress - Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.

AI Summary: Novo Nordisk has vowed to take legal action after discovering that competitors – including Hims & Hers – plan to market a compounded, lower‐priced version of its new Wegovy weight‐loss pill. The company is mobilizing its legal team to protect its intellectual property amid fierce market competition.

#obesity #healthcare #pharmaceuticals #drugpricing #novonordisk #weightloss #drugdevelopment #digitalhealth
Obesity RSSHealthcare RSSPharmaceuticals RSSDrug Pricing RSSNovo Nordisk RSSWeight Loss RSSDrug Development RSSDigital Health RSS

Novo Nordisk to expand Irish factory for Wegovy pill

4 months / endpoints / Anna Brown

Blockbuster weight loss drugs like Ozempic deliver big results but face big questions

5 months / sciencedaily

Why people won't quit a weight loss drug, even when it makes them feel sick

5 months / medicalxpress

FDA to Novo Nordisk: Correct ‘misleading’ GLP-1 pill TV ad

5 months / beckershospitalreview / Erica Cerutti

The fallout from Novo vs. Hims

5 months / endpoints / Lydia Ramsey Pflanzer

Hims pulls cheaper Wegovy pill after federal scrutiny

5 months / medicalxpress

Hims retreats from weight loss pill launch as Novo, FDA pressure mounts

5 months / fiercehealthcare

After industry pressure, Hims & Hers stops selling Wegovy pill

5 months / beckershospitalreview / Paige Twenter

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

5 months / endpoints / Elizabeth Cairns

'Weight-loss jab helped me find my cancer'

5 months / bbc

Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny

5 months / nytimes / Rebecca Robbins

Hims says it will stop selling GLP-1 pill, after legal pressure from US

5 months / endpoints / Drew Armstrong

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

5 months / endpoints / Max Gelman

US calls for DOJ investigation of Hims over GLP-1 drugs

5 months / endpoints / Shelby Livingston

Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications

5 months / medicalxpress

FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push

5 months / fiercehealthcare

FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

5 months / endpoints / Max Bayer

Novo's threat to sue Hims over Wegovy pill faces legal hurdle

5 months / endpoints / Shelby Livingston

War breaks out over GLP-1 pills

5 months / beckershospitalreview / Paige Twenter

Novo Nordisk vows legal action to protect Wegovy pill

5 months / medicalxpress

Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

5 months / fiercehealthcare

Telehealth provider Hims goes after Novo's weight-loss pill with compounded version

5 months / endpoints / Zachary Brennan

Back to Top / Thu, February 5, 2026, 3:23 pm / permalink 18807 / 22 stories in 5 months /




Related Stories

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 4 months

JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 5 months

Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 6 months

Novo launches high‑dose Wegovy in US at $399 for self‑pay patients / 3 months

Amazon expands access to Ozempic pill with delivery and kiosks / 2 months

Novo Nordisk and Hims bury the hatchet and carve a deal / 3 months

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 4 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Behavioral Health, Supplements, Olfaction, Animal Health and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.